"Our development of a novel pharmacological assay allows us to directly assess glutaminase inhibition in patients receiving CB-839 from just a single post-dose tumor biopsy, allowing us to get confirmation that CB-839 is reaching the tumor and inhibiting the target," said
The data were presented in a poster titled, "A Novel Pharmacodynamic Assay to
Additional data showed that glutaminase mRNA expression, protein expression, and enzyme activity are all elevated in human TNBC tumors when compared to ER+ breast cancer tumors, or normal breast tissue. In breast cancer cell lines, expression of glutaminase is a biomarker that predicts sensitivity to CB-839.
Two posters will be presented by Calithera's collaborators. Details for the presentations are as follows:
Signaling consequences and rational therapeutic combinations with glutaminase inhibitor, CB-839, in basal breast cancer |
Abstract # P1-08-01 |
Jennifer Dennison, Ph,D., MD Anderson |
Poster Session 1 |
Wednesday December 10, 2014, 5:00-7:00 PM |
Halls A-B, Henry B. Gonzalez Convention Center |
Glutamine metabolism promotes survival through the unfolded protein response in endocrine resistant breast cancer |
Abstract # P3-05-11 |
Ayesha Shajahan-Haq, Ph.D., Georgetown University |
Poster Session 3 |
Thursday, December 11, 2014 at 5:00-7:00 PM |
Halls A-B, Henry B. Gonzalez Convention Center |
About Calithera Biosciences
Forward-Looking Statements
This news release contains forward-looking statements by Calithera that involve risks and uncertainties. Actual results may differ from Calithera's expectations and important factors that could cause actual results to differ materially. Calithera's product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, future clinical trials may not show significant glutaminase inhibition following oral administration of CB-839. Furthermore, Calithera's product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Quarterly Report on Form 10-Q for the period ended
CONTACT:Jennifer McNealey ir@Calithera.com 650-870-1071